Revenue
0 USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
Rapport Therapeutics, Inc.
EDGAR16 filing records in this dataset, filed from 2024-05-17 to 2026-10-30. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating cash flow
-41.5 million USD
2026 Q2 · USD
Free cash flow
-41.5 million USD
2026 Q2 · USD
- Cash and cash equivalents
- 63.6 million USD Source
Exact value
63612000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 48 million shares Source
Exact value
47955079 shares
Reported share-count change
31.39% · 11.5 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Net income
-137 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Operating cash flow
-96.7 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -62772000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -45307000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -87473000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -62772000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -13061000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -54516000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -13061000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure
467 thousand USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Capital expenditure: 447000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 313000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 616000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 447000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 86000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 164000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 86000 USD · 2026-01-01 – 2026-03-31 Source
Free cash flow
-97.1 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -62772000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -45307000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -87473000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -62772000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -13061000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -54516000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -13061000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 447000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 313000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 616000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 447000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 86000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 164000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 86000 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-30.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 3 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- Capital expenditure: 3 of 11 periods available· newest 2025-12-31
- Total assets: 3 of 11 periods available· newest 2025-12-31
- Total liabilities: 3 of 11 periods available· newest 2025-12-31
- Current assets: 3 of 11 periods available· newest 2025-12-31
- Current liabilities: 3 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 3 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 33.18 millionPrior period
−USD 78.31 million
–
Current period
−USD 111.48 million
–
Exact inputs and evidence
-111483000 − -78307000 = -33176000 USD
-78307000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-111483000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 22.65 millionPrior period
−USD 64.83 million
–
Current period
−USD 87.47 million
–
Exact inputs and evidence
-87473000 − -64828000 = -22645000 USD
-64828000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-87473000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-74.4%Prior period
USD 2.41 million
–
Current period
USD 616,000
–
Exact inputs and evidence
616000 − 2405000 = -1789000 USD
2405000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source616000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 34.79 million Exact valueExact value: -34786000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 27.18 million Exact valueExact value: -27181000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.64 million Exact valueExact value: 1636000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 28.82 million Calculation and evidence-27181000 − 1636000 USD Exact free cash flow: -28817000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 78.31 million Exact valueExact value: -78307000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 64.83 million Exact valueExact value: -64828000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2.41 million Exact valueExact value: 2405000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 67.23 million Calculation and evidence-64828000 − 2405000 USD Exact free cash flow: -67233000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 111.48 million Exact valueExact value: -111483000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 87.47 million Exact valueExact value: -87473000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 616,000 Exact valueExact value: 616000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 88.09 million Calculation and evidence-87473000 − 616000 USD Exact free cash flow: -88089000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
16 filings · 715 latest values · 715 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0002012593, 2012593, RAPP, edgar:2012593
Also known as Rapport Therapeutics, Inc.